Literature DB >> 36243841

PTEN in Immunity.

Antonella Papa1, Pier Paolo Pandolfi2.   

Abstract

The tumor suppressor PTEN (Phosphatase and Tensin homolog deleted on Chromosome 10) executes critical biological functions that limit cellular growth and proliferation. PTEN inhibits activation of the proto-oncogenic PI3K pathway and is required during embryogenesis and to suppress tumor formation and cancer progression throughout life. The critical role that PTEN plays in restraining cellular growth has been validated through the generation of a number of animal models whereby PTEN inactivation invariably leads to tumor formation in a cell-autonomous fashion. However, the increasing understanding of the mechanisms through which the immune system contributes to suppressing tumor progression has highlighted how, in a cell non-autonomous fashion, cancer-associated mutations can indirectly enhance oncogenesis by evading immune cell recognition. Here, in light of the essential role of PTEN in the regulation of immune cell development and function, and based on recent findings showing that PTEN loss can promote resistance to immune checkpoint inhibitors in various tumor types, we re-evaluate our understanding of the mechanisms through which PTEN functions as a tumor suppressor and postulate that this task is achieved through a combination of cell autonomous and non-autonomous effects. We highlight some of the critical studies that have delineated the functional role of PTEN in immune cell development and blood malignancies and propose new strategies for the treatment of PTEN loss-driven diseases.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer resistance; Immune cell development; Immunotherapy; PTEN; Tumor suppression

Mesh:

Substances:

Year:  2022        PMID: 36243841     DOI: 10.1007/978-3-031-06566-8_4

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.737


  69 in total

Review 1.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

2.  Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN.

Authors:  Jodi L Buckler; Patrick T Walsh; Paige M Porrett; Yongwon Choi; Laurence A Turka
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

3.  PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.

Authors:  P L Dahia; R C Aguiar; J Alberta; J B Kum; S Caron; H Sill; D J Marsh; J Ritz; A Freedman; C Stiles; C Eng
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

4.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice.

Authors:  B E Clausen; C Burkhardt; W Reith; R Renkawitz; I Förster
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

5.  Impaired Fas response and autoimmunity in Pten+/- mice.

Authors:  A Di Cristofano; P Kotsi; Y F Peng; C Cordon-Cardo; K B Elkon; P P Pandolfi
Journal:  Science       Date:  1999-09-24       Impact factor: 47.728

Review 6.  Mutations of the human PTEN gene.

Authors:  D Bonneau; M Longy
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

7.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

8.  Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome.

Authors:  June-Won Cheong; Ju In Eom; Ho-Young Maeng; Seung Tae Lee; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

9.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

Review 10.  Recent advances in PTEN signalling axes in cancer.

Authors:  Jonathan Tak-Sum Chow; Leonardo Salmena
Journal:  Fac Rev       Date:  2020-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.